We like funds with great long-term performance, but if short-term returns get red hot, we get a little wary. As you may ...

Investing rewards are a different story. Some of the best investors are contrarians that uncover value by zigging while the ...

I bought a Tesla Model 3 about five years ago. I was going to buy a Volkswagen, but the car dealer was so argumentative, and when he found out that I lived in West Hollywood, he said, "What do you ...

Louis Navellier says he isn't selling any Nvidia shares now - regardless of earnings There are many reasons to be bullish about Nvidia Corp. besides its strong forecasted third-quarter sales and ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

Similarities abound to Michael Jordan and the Chicago Bulls - only this time for Nvidia bulls During the 1995-'96 NBA season, Chicago Bulls tickets were impossible to get, but my father and I were ...

Active ETF launches are outpacing index trackers, but most are not the old-fashioned stock-picking kind. Many highly ...

We think Keysight Technologies is the leader in communications testing and measurement solutions, and offers a vendor-agnostic way to invest in the rapidly growing 5G and high-speed networking markets ...

To these questions, neither Musk nor his fellow efficiency czar (and, according to some estimates, fellow billionaire) Vivek Ramaswamy have provided any answers. The men are tasked with leading DOGE, ...

Hanesbrands is the market leader in basic innerwear in multiple countries. We believe its key innerwear brands, like Hanes and Bonds in Australia, achieve premium pricing. Our narrow moat rating on ...

I have very high limits, so charges barely make a blip on my credit-utilization ratio' Okay, talk me down. I have 18 credit cards and would like to close five of them - all at once. Actually, I'd like ...

Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...